Nagashubha Bobbarjang, Uma Maheshwara Rao V, Iswarya S, Karishma Pn, Mythri G, Tariq Ahmad Khari, M. Gs, Charitha B, Kiran Sai Maccha
This review dives into the fascinating world of Bougainvillea, exploring its chemical makeup and potential health benefits. While research encompasses 18 species, most studies (phytochemical, pharmacological, and toxicological) have focused on just four species and their cultivars, along with one hybrid. Interestingly, some Bougainvillea species already have a history of use in traditional medicine. Scientific investigations have confirmed the presence of diverse chemical compounds within Bougainvillea, including aliphatic hydrocarbons, fatty acids, volatile oils, phenolics, flavonoids, and terpenes. These studies suggest that not only the extracts but also isolated active components from Bougainvillea exhibit a wide range of pharmacological activities. This exciting potential pave the way for further exploration of Bougainvillea as a source of valuable therapeutic compounds. To unlock the full potential of Bougainvillea, future research should delve deeper into the phytochemical, pharmacological, and toxicological properties of all species, cultivars, and hybrids. Understanding mechanisms of action, safety, and efficacy is crucial for responsible development of any potential medications derived from this beautiful and promising genus.
{"title":"Unveiling the Secrets of Bougainvillea: A Review of Phytochemical and Pharmacological Properties","authors":"Nagashubha Bobbarjang, Uma Maheshwara Rao V, Iswarya S, Karishma Pn, Mythri G, Tariq Ahmad Khari, M. Gs, Charitha B, Kiran Sai Maccha","doi":"10.26452/fjphs.v4i1.586","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.586","url":null,"abstract":"This review dives into the fascinating world of Bougainvillea, exploring its chemical makeup and potential health benefits. While research encompasses 18 species, most studies (phytochemical, pharmacological, and toxicological) have focused on just four species and their cultivars, along with one hybrid. Interestingly, some Bougainvillea species already have a history of use in traditional medicine. Scientific investigations have confirmed the presence of diverse chemical compounds within Bougainvillea, including aliphatic hydrocarbons, fatty acids, volatile oils, phenolics, flavonoids, and terpenes. These studies suggest that not only the extracts but also isolated active components from Bougainvillea exhibit a wide range of pharmacological activities. This exciting potential pave the way for further exploration of Bougainvillea as a source of valuable therapeutic compounds. To unlock the full potential of Bougainvillea, future research should delve deeper into the phytochemical, pharmacological, and toxicological properties of all species, cultivars, and hybrids. Understanding mechanisms of action, safety, and efficacy is crucial for responsible development of any potential medications derived from this beautiful and promising genus.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140258440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joan Vijetha R, Kaviyarasan K, Annie Bhuvana Mary A, Gopinath N, Sam Daniel J, Vasanth B
Metformin hydrochloride (MH) is synthesis of N, N-dimethylguanidine medicament which is used for the treat of type-II diabetes which was discovered by Emil Werner and James Bell, which belongs to BCS class III. MH is chosen first-line oral blood glucose-lowering medication for the treatment of type-II diabetes, almost around 120 million patients are using worldwide. It works by decreasing the hepatic glucose production through a mild inhibition of mitochondrial respiration chain complex. MH which has been further tested and also proven that it can be used for various treatments such as, weight loss, improving fertility, slow the growth of tumour, anti-malaria, and few others. MH is synthesis from Galega officinalis which is a perennial plant that blooms in the summer and is native to most temperate areas. In this study, complete information about the drug history, drug profile, pharmacokinetic, drug interaction, clinical symptoms, advantages & disadvantages of MH and reason why its getting banned has been explained in detail.
盐酸二甲双胍（MH）是由 N，N-二甲基胍合成的药物，用于治疗 II 型糖尿病，由 Emil Werner 和 James Bell 发现，属于 BCS III 类。MH 被选为治疗 II 型糖尿病的一线口服降糖药，全球约有 1.2 亿患者在使用。它的作用原理是通过轻度抑制线粒体呼吸链复合物来减少肝糖生成。经进一步测试证明，MH 可用于减肥、提高生育能力、延缓肿瘤生长、抗疟疾等多种治疗。MH 是由 Galega officinalis 合成的，Galega officinalis 是一种多年生植物，夏季开花，原产于大多数温带地区。本研究详细介绍了 MH 的药物历史、药物概况、药代动力学、药物相互作用、临床症状、优缺点以及被禁用的原因。
{"title":"Metformin hydrochloride: The most prescribed treatment for type II diabetes -gets banned","authors":"Joan Vijetha R, Kaviyarasan K, Annie Bhuvana Mary A, Gopinath N, Sam Daniel J, Vasanth B","doi":"10.26452/fjphs.v4i1.585","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.585","url":null,"abstract":"Metformin hydrochloride (MH) is synthesis of N, N-dimethylguanidine medicament which is used for the treat of type-II diabetes which was discovered by Emil Werner and James Bell, which belongs to BCS class III. MH is chosen first-line oral blood glucose-lowering medication for the treatment of type-II diabetes, almost around 120 million patients are using worldwide. It works by decreasing the hepatic glucose production through a mild inhibition of mitochondrial respiration chain complex. MH which has been further tested and also proven that it can be used for various treatments such as, weight loss, improving fertility, slow the growth of tumour, anti-malaria, and few others. MH is synthesis from Galega officinalis which is a perennial plant that blooms in the summer and is native to most temperate areas. In this study, complete information about the drug history, drug profile, pharmacokinetic, drug interaction, clinical symptoms, advantages & disadvantages of MH and reason why its getting banned has been explained in detail.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"6 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140258538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bhaskar Reddy Kesavan, Audinarayana Nelavala, Soujanya G S
This study aims to optimize Simvastatin-loaded Solid Lipid Nanoparticles (SLNs) using a 2^k factorial design approach. Simvastatin, a widely used cholesterol-lowering drug, faces bioavailability challenges, prompting the use of nanotechnology for drug delivery. The study focuses on lipid concentration, surfactant concentration, and homogenization speed as critical factors influencing SLN characteristics. These factors were chosen based on their potential impact on SLN physicochemical properties like particle size, polydispersity index, and drug entrapment efficiency. Through systematic variation of factor levels, a matrix of experiments will be created, measuring responses (particle size, polydispersity index, and drug entrapment efficiency) for each run. Statistical analysis, including ANOVA, will assess factor significance and interactions. The study aims to reveal critical parameters affecting Simvastatin-loaded SLN formulation. The optimized formulation targets uniform and stable nanoparticles with enhanced drug entrapment, enhancing Simvastatin bioavailability. The factorial design method offers a systematic, resource-efficient approach for simultaneously screening and optimizing multiple factors, streamlining the experimental process.Top of Form
{"title":"Screening of important factors using factorial design to predict simvastatin loaded solid lipid nanoparticles","authors":"Bhaskar Reddy Kesavan, Audinarayana Nelavala, Soujanya G S","doi":"10.26452/fjphs.v4i1.581","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.581","url":null,"abstract":"This study aims to optimize Simvastatin-loaded Solid Lipid Nanoparticles (SLNs) using a 2^k factorial design approach. Simvastatin, a widely used cholesterol-lowering drug, faces bioavailability challenges, prompting the use of nanotechnology for drug delivery. The study focuses on lipid concentration, surfactant concentration, and homogenization speed as critical factors influencing SLN characteristics. These factors were chosen based on their potential impact on SLN physicochemical properties like particle size, polydispersity index, and drug entrapment efficiency. Through systematic variation of factor levels, a matrix of experiments will be created, measuring responses (particle size, polydispersity index, and drug entrapment efficiency) for each run. Statistical analysis, including ANOVA, will assess factor significance and interactions. The study aims to reveal critical parameters affecting Simvastatin-loaded SLN formulation. The optimized formulation targets uniform and stable nanoparticles with enhanced drug entrapment, enhancing Simvastatin bioavailability. The factorial design method offers a systematic, resource-efficient approach for simultaneously screening and optimizing multiple factors, streamlining the experimental process.Top of Form","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"392 7-8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139848087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bhaskar Reddy Kesavan, Audinarayana Nelavala, Soujanya G S
This study aims to optimize Simvastatin-loaded Solid Lipid Nanoparticles (SLNs) using a 2^k factorial design approach. Simvastatin, a widely used cholesterol-lowering drug, faces bioavailability challenges, prompting the use of nanotechnology for drug delivery. The study focuses on lipid concentration, surfactant concentration, and homogenization speed as critical factors influencing SLN characteristics. These factors were chosen based on their potential impact on SLN physicochemical properties like particle size, polydispersity index, and drug entrapment efficiency. Through systematic variation of factor levels, a matrix of experiments will be created, measuring responses (particle size, polydispersity index, and drug entrapment efficiency) for each run. Statistical analysis, including ANOVA, will assess factor significance and interactions. The study aims to reveal critical parameters affecting Simvastatin-loaded SLN formulation. The optimized formulation targets uniform and stable nanoparticles with enhanced drug entrapment, enhancing Simvastatin bioavailability. The factorial design method offers a systematic, resource-efficient approach for simultaneously screening and optimizing multiple factors, streamlining the experimental process.Top of Form
{"title":"Screening of important factors using factorial design to predict simvastatin loaded solid lipid nanoparticles","authors":"Bhaskar Reddy Kesavan, Audinarayana Nelavala, Soujanya G S","doi":"10.26452/fjphs.v4i1.581","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.581","url":null,"abstract":"This study aims to optimize Simvastatin-loaded Solid Lipid Nanoparticles (SLNs) using a 2^k factorial design approach. Simvastatin, a widely used cholesterol-lowering drug, faces bioavailability challenges, prompting the use of nanotechnology for drug delivery. The study focuses on lipid concentration, surfactant concentration, and homogenization speed as critical factors influencing SLN characteristics. These factors were chosen based on their potential impact on SLN physicochemical properties like particle size, polydispersity index, and drug entrapment efficiency. Through systematic variation of factor levels, a matrix of experiments will be created, measuring responses (particle size, polydispersity index, and drug entrapment efficiency) for each run. Statistical analysis, including ANOVA, will assess factor significance and interactions. The study aims to reveal critical parameters affecting Simvastatin-loaded SLN formulation. The optimized formulation targets uniform and stable nanoparticles with enhanced drug entrapment, enhancing Simvastatin bioavailability. The factorial design method offers a systematic, resource-efficient approach for simultaneously screening and optimizing multiple factors, streamlining the experimental process.Top of Form","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":" 55","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139788218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
One of the many different carriers for getting a drug molecule to its site of action is a niosome, also known as a nonionic surfactant vesicle. Hydrophilic and hydrophobic medicines can both be trapped by them. The primary purpose of the medication hydrochlorothiazide, an angiotensin II type 1 receptor (AT1) antagonist, is to treat high blood pressure. Using cholesterol and nonionic surfactants (span 60) at varying concentrations, niosomes containing hydrochlorothiazide were created by the thin film hydration method. FTIR investigations, in vitro release studies, vesicular diameter, drug content, repeatability, shape and size distribution microphotography, and entrapment efficiency were all assessed for each niosome formulation.According to the findings, entrapment efficiency rises with surfactant concentration in all developed niosomal formulations. Low SD was found for the drug content, which ranged from 90.060.57 to 96.150.42. It was discovered that niosomes ranged in size from 0.280±0.098µm to 0.299±0.044µm and had a spherical shape. The medicine and formulation additives did not interact, according to the IR spectral analysis. Membrane diffusion cells were used to study the in vitro dissolution parameters. The findings indicate that formulation F6 exhibits a more controlled release action compared to the other formulation, with a 'n' value of 0.917, indicating that zero order kinetics were used to release the medication.
{"title":"Formulation, Evaluation and Characterization of Hydrochlorothiazide Niosomes","authors":"Ameer Pasha Shaik, Vinod Naidu","doi":"10.26452/fjphs.v4i1.566","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.566","url":null,"abstract":"One of the many different carriers for getting a drug molecule to its site of action is a niosome, also known as a nonionic surfactant vesicle. Hydrophilic and hydrophobic medicines can both be trapped by them. The primary purpose of the medication hydrochlorothiazide, an angiotensin II type 1 receptor (AT1) antagonist, is to treat high blood pressure. Using cholesterol and nonionic surfactants (span 60) at varying concentrations, niosomes containing hydrochlorothiazide were created by the thin film hydration method. FTIR investigations, in vitro release studies, vesicular diameter, drug content, repeatability, shape and size distribution microphotography, and entrapment efficiency were all assessed for each niosome formulation.According to the findings, entrapment efficiency rises with surfactant concentration in all developed niosomal formulations. Low SD was found for the drug content, which ranged from 90.060.57 to 96.150.42. It was discovered that niosomes ranged in size from 0.280±0.098µm to 0.299±0.044µm and had a spherical shape. The medicine and formulation additives did not interact, according to the IR spectral analysis. Membrane diffusion cells were used to study the in vitro dissolution parameters. The findings indicate that formulation F6 exhibits a more controlled release action compared to the other formulation, with a 'n' value of 0.917, indicating that zero order kinetics were used to release the medication.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"248 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139819219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
One of the many different carriers for getting a drug molecule to its site of action is a niosome, also known as a nonionic surfactant vesicle. Hydrophilic and hydrophobic medicines can both be trapped by them. The primary purpose of the medication hydrochlorothiazide, an angiotensin II type 1 receptor (AT1) antagonist, is to treat high blood pressure. Using cholesterol and nonionic surfactants (span 60) at varying concentrations, niosomes containing hydrochlorothiazide were created by the thin film hydration method. FTIR investigations, in vitro release studies, vesicular diameter, drug content, repeatability, shape and size distribution microphotography, and entrapment efficiency were all assessed for each niosome formulation.According to the findings, entrapment efficiency rises with surfactant concentration in all developed niosomal formulations. Low SD was found for the drug content, which ranged from 90.060.57 to 96.150.42. It was discovered that niosomes ranged in size from 0.280±0.098µm to 0.299±0.044µm and had a spherical shape. The medicine and formulation additives did not interact, according to the IR spectral analysis. Membrane diffusion cells were used to study the in vitro dissolution parameters. The findings indicate that formulation F6 exhibits a more controlled release action compared to the other formulation, with a 'n' value of 0.917, indicating that zero order kinetics were used to release the medication.
{"title":"Formulation, Evaluation and Characterization of Hydrochlorothiazide Niosomes","authors":"Ameer Pasha Shaik, Vinod Naidu","doi":"10.26452/fjphs.v4i1.566","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.566","url":null,"abstract":"One of the many different carriers for getting a drug molecule to its site of action is a niosome, also known as a nonionic surfactant vesicle. Hydrophilic and hydrophobic medicines can both be trapped by them. The primary purpose of the medication hydrochlorothiazide, an angiotensin II type 1 receptor (AT1) antagonist, is to treat high blood pressure. Using cholesterol and nonionic surfactants (span 60) at varying concentrations, niosomes containing hydrochlorothiazide were created by the thin film hydration method. FTIR investigations, in vitro release studies, vesicular diameter, drug content, repeatability, shape and size distribution microphotography, and entrapment efficiency were all assessed for each niosome formulation.According to the findings, entrapment efficiency rises with surfactant concentration in all developed niosomal formulations. Low SD was found for the drug content, which ranged from 90.060.57 to 96.150.42. It was discovered that niosomes ranged in size from 0.280±0.098µm to 0.299±0.044µm and had a spherical shape. The medicine and formulation additives did not interact, according to the IR spectral analysis. Membrane diffusion cells were used to study the in vitro dissolution parameters. The findings indicate that formulation F6 exhibits a more controlled release action compared to the other formulation, with a 'n' value of 0.917, indicating that zero order kinetics were used to release the medication.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139879364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Colorectal cancer is the second leading cause of cancer-related death and the third most common cancer globally. For loco regional colon cancer, surgery is the sole curative option. Adjuvant chemotherapy aims to eliminate micro metastases and increase survival. It has been most convincingly proven in stage III illness, even though there is ongoing debate on the usefulness of adjuvant chemotherapy for stage II illness. For the past fifteen years, six months of adjuvant chemotherapy with an oxaliplatin-based chemotherapy has been the accepted standard of care for stage III colon cancer. It is still advised to use 6 months of adjuvant chemotherapy for individuals with stage II illness and high clinicopathological risk. Chemo radiation therapy (CRT) is frequently used as neoadjuvant or adjuvant therapy in the treatment of stage II and stage III rectal cancers because this cancer type has a higher risk of local recurrence than other cancer types.
结肠直肠癌是导致癌症相关死亡的第二大原因，也是全球第三大常见癌症。对于局部区域性结肠癌，手术是唯一的根治选择。辅助化疗旨在消除微小转移灶，提高生存率。尽管关于辅助化疗对 II 期癌症是否有用的争论仍在继续，但辅助化疗在 III 期癌症中的疗效已得到最令人信服的证实。在过去的 15 年中，以奥沙利铂为基础的 6 个月辅助化疗一直是公认的 III 期结肠癌治疗标准。对于病情处于 II 期且临床病理风险较高的患者，仍建议使用 6 个月的辅助化疗。化疗放疗（CRT）经常作为新辅助或辅助疗法用于 II 期和 III 期直肠癌的治疗，因为这种癌症类型的局部复发风险高于其他癌症类型。
{"title":"An expatiate review on adjuvant chemotherapy of colorectal cancer","authors":"Shahireen Shahireen, Vipplavi Eka, Kavya Rachamsetty, Dhachinamoorthi Duraiswamy, Rama Chandra Reddy L","doi":"10.26452/fjphs.v4i1.567","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.567","url":null,"abstract":"Colorectal cancer is the second leading cause of cancer-related death and the third most common cancer globally. For loco regional colon cancer, surgery is the sole curative option. Adjuvant chemotherapy aims to eliminate micro metastases and increase survival. It has been most convincingly proven in stage III illness, even though there is ongoing debate on the usefulness of adjuvant chemotherapy for stage II illness. For the past fifteen years, six months of adjuvant chemotherapy with an oxaliplatin-based chemotherapy has been the accepted standard of care for stage III colon cancer. It is still advised to use 6 months of adjuvant chemotherapy for individuals with stage II illness and high clinicopathological risk. Chemo radiation therapy (CRT) is frequently used as neoadjuvant or adjuvant therapy in the treatment of stage II and stage III rectal cancers because this cancer type has a higher risk of local recurrence than other cancer types.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"84 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139884777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alagusundaram M, Priyanka Keshri, Pratibha Sharma, Nem Kumar Jain, China Babu Dara
Metoprolol succinate-controlled release matrix tablets were made utilizing the wet granulation process with various ratio of Hydroxypropyl methyl cellulose (HPMC K4M). Isopropyl alcohol is used as a granulating agent in the Povidone (PVP K30) solution. In addition to being utilised as diluents to raise the weight of the tablets, magnesium stearate and talc were added to enhance the granules' flow ability during tablet compression. The crushed tablets underwent physicochemical characteristics, in-vitro and kinetic tests, and the micromeritic properties of the generated granules were evaluated. In every formulation, results were nearly satisfactory, with M4 being the best among the others. All of the formulations showed good correlation. The drug diffusion kinetics from matrix tablets appeared to be zero order, and the release mechanism was diffusion regulated.
{"title":"Formulation and characterization: Metoprolol succinate controlled release matrix tablets","authors":"Alagusundaram M, Priyanka Keshri, Pratibha Sharma, Nem Kumar Jain, China Babu Dara","doi":"10.26452/fjphs.v4i1.568","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.568","url":null,"abstract":"Metoprolol succinate-controlled release matrix tablets were made utilizing the wet granulation process with various ratio of Hydroxypropyl methyl cellulose (HPMC K4M). Isopropyl alcohol is used as a granulating agent in the Povidone (PVP K30) solution. In addition to being utilised as diluents to raise the weight of the tablets, magnesium stearate and talc were added to enhance the granules' flow ability during tablet compression. The crushed tablets underwent physicochemical characteristics, in-vitro and kinetic tests, and the micromeritic properties of the generated granules were evaluated. In every formulation, results were nearly satisfactory, with M4 being the best among the others. All of the formulations showed good correlation. The drug diffusion kinetics from matrix tablets appeared to be zero order, and the release mechanism was diffusion regulated.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"71 3-4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139893111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alagusundaram M, Priyanka Keshri, Pratibha Sharma, Nem Kumar Jain, China Babu Dara
Metoprolol succinate-controlled release matrix tablets were made utilizing the wet granulation process with various ratio of Hydroxypropyl methyl cellulose (HPMC K4M). Isopropyl alcohol is used as a granulating agent in the Povidone (PVP K30) solution. In addition to being utilised as diluents to raise the weight of the tablets, magnesium stearate and talc were added to enhance the granules' flow ability during tablet compression. The crushed tablets underwent physicochemical characteristics, in-vitro and kinetic tests, and the micromeritic properties of the generated granules were evaluated. In every formulation, results were nearly satisfactory, with M4 being the best among the others. All of the formulations showed good correlation. The drug diffusion kinetics from matrix tablets appeared to be zero order, and the release mechanism was diffusion regulated.
{"title":"Formulation and characterization: Metoprolol succinate controlled release matrix tablets","authors":"Alagusundaram M, Priyanka Keshri, Pratibha Sharma, Nem Kumar Jain, China Babu Dara","doi":"10.26452/fjphs.v4i1.568","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.568","url":null,"abstract":"Metoprolol succinate-controlled release matrix tablets were made utilizing the wet granulation process with various ratio of Hydroxypropyl methyl cellulose (HPMC K4M). Isopropyl alcohol is used as a granulating agent in the Povidone (PVP K30) solution. In addition to being utilised as diluents to raise the weight of the tablets, magnesium stearate and talc were added to enhance the granules' flow ability during tablet compression. The crushed tablets underwent physicochemical characteristics, in-vitro and kinetic tests, and the micromeritic properties of the generated granules were evaluated. In every formulation, results were nearly satisfactory, with M4 being the best among the others. All of the formulations showed good correlation. The drug diffusion kinetics from matrix tablets appeared to be zero order, and the release mechanism was diffusion regulated.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"106 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139832963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Colorectal cancer is the second leading cause of cancer-related death and the third most common cancer globally. For loco regional colon cancer, surgery is the sole curative option. Adjuvant chemotherapy aims to eliminate micro metastases and increase survival. It has been most convincingly proven in stage III illness, even though there is ongoing debate on the usefulness of adjuvant chemotherapy for stage II illness. For the past fifteen years, six months of adjuvant chemotherapy with an oxaliplatin-based chemotherapy has been the accepted standard of care for stage III colon cancer. It is still advised to use 6 months of adjuvant chemotherapy for individuals with stage II illness and high clinicopathological risk. Chemo radiation therapy (CRT) is frequently used as neoadjuvant or adjuvant therapy in the treatment of stage II and stage III rectal cancers because this cancer type has a higher risk of local recurrence than other cancer types.
结肠直肠癌是导致癌症相关死亡的第二大原因，也是全球第三大常见癌症。对于局部区域性结肠癌，手术是唯一的根治选择。辅助化疗旨在消除微小转移灶，提高生存率。尽管关于辅助化疗对 II 期癌症是否有用的争论仍在继续，但辅助化疗在 III 期癌症中的疗效已得到最令人信服的证实。在过去的 15 年中，以奥沙利铂为基础的 6 个月辅助化疗一直是公认的 III 期结肠癌治疗标准。对于病情处于 II 期且临床病理风险较高的患者，仍建议使用 6 个月的辅助化疗。化疗放疗（CRT）经常作为新辅助或辅助疗法用于 II 期和 III 期直肠癌的治疗，因为这种癌症类型的局部复发风险高于其他癌症类型。
{"title":"An expatiate review on adjuvant chemotherapy of colorectal cancer","authors":"Shahireen Shahireen, Vipplavi Eka, Kavya Rachamsetty, Dhachinamoorthi Duraiswamy, Rama Chandra Reddy L","doi":"10.26452/fjphs.v4i1.567","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.567","url":null,"abstract":"Colorectal cancer is the second leading cause of cancer-related death and the third most common cancer globally. For loco regional colon cancer, surgery is the sole curative option. Adjuvant chemotherapy aims to eliminate micro metastases and increase survival. It has been most convincingly proven in stage III illness, even though there is ongoing debate on the usefulness of adjuvant chemotherapy for stage II illness. For the past fifteen years, six months of adjuvant chemotherapy with an oxaliplatin-based chemotherapy has been the accepted standard of care for stage III colon cancer. It is still advised to use 6 months of adjuvant chemotherapy for individuals with stage II illness and high clinicopathological risk. Chemo radiation therapy (CRT) is frequently used as neoadjuvant or adjuvant therapy in the treatment of stage II and stage III rectal cancers because this cancer type has a higher risk of local recurrence than other cancer types.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"60 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139824702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：